BackgroundCheck.run
Search For

Jose D Murga, 493642 205Th St, Flushing, NY 11361

Known as:
Jose David Murga Jose Foglietta Jose A

Jose Murga Phones & Addresses

3642 205Th St, Bayside, NY 11361    347-5027015   

3416 Jordan St, Flushing, NY 11358    718-4602596   

Jamaica, NY   

100 Franklin St, Morristown, NJ 07960    973-2679398   

Work

Company: Progenics pharmaceuticals, inc - Tarrytown, NY 2011 Position: Senior research scientist ii - oncology

Education

School / High School: New York Medical College- Valhalla, NY 2007 Specialities: MS in Biostatistics

Skills

Drug Discovery • ADC • Cell & Molecular Biology • Flow Cytometry • LIMS • HTS • see technical skills section
Get Report
Control this profile

Mentions for Jose D Murga

Jose Murga resumes & CV records

Resumes

Jose Murga Photo 35

Senior Research Scientist Ii At Progenics Pharmaceuticals

Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Progenics Pharmaceuticals - Tarrytown, NY Sep 2002 - Mar 2013
Senior Research Scientist II Novartis - Summit, NJ Sep 2001 - Aug 2002
Associate Research Scientist
Education:
New York Medical College
Queens College
Jose Murga Photo 36

Research Scientist At Progenics Pharmaceuticals

Location:
Greater New York City Area
Industry:
Pharmaceuticals
Jose Murga Photo 37

Jose Murga

Jose Murga Photo 38

Jose Murga - Bayside, NY

Work:
Progenics Pharmaceuticals, Inc - Tarrytown, NY 2011 to 2014
Senior Research Scientist II - Oncology Progenics Pharmaceuticals, Inc - Tarrytown, NY 2008 to 2011
Senior Research Scientist - Virology Progenics Pharmaceuticals, Inc - Tarrytown, NY 2006 to 2008
Research Scientist - Virology Progenics Pharmaceuticals, Inc - Tarrytown, NY 2004 to 2006
Associate Research Scientist - Virology Progenics Pharmaceuticals, Inc - Tarrytown, NY 2002 to 2004
Assistant Research Scientist - Virology Novartis Pharmaceuticals - Summit, NJ 2001 to 2002
Associate Research Scientist - Metabolic and Cardiovascular Diseases Department CUNY Research Foundation - Flushing, NY 1997 to 2001
Undergraduate/Graduate Research Assistant - Biology Department
Education:
New York Medical College - Valhalla, NY 2007
MS in Biostatistics Graduate School CUNY - Flushing, NY 2001
MA in Biology Queens College CUNY - Flushing, NY 1997
BA in Biology
Skills:
Drug Discovery, ADC, Cell & Molecular Biology, Flow Cytometry, LIMS, HTS, see technical skills section

Publications & IP owners

Us Patents

Methods For Reducing Viral Load In Hiv-1-Infected Patients

US Patent:
2007002, Feb 1, 2007
Filed:
Jul 21, 2006
Appl. No.:
11/491330
Inventors:
William Olson - Ossining NY, US
Paul Maddon - Scarsdale NY, US
Daniel Pevear - Medford MA, US
Robert Israel - Suffern NY, US
Jose Murga - Rosedale NY, US
International Classification:
C12Q 1/68
G01N 33/53
US Classification:
435006000, 435007100
Abstract:
This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

Methods For Reducing Viral Load In Hiv-1-Infected Patients

US Patent:
2008024, Oct 2, 2008
Filed:
Aug 20, 2007
Appl. No.:
11/894762
Inventors:
William C. Olson - Ossining NY, US
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Medford MA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
International Classification:
A61K 39/395
A61P 43/00
US Classification:
4241331
Abstract:
This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

Methods For Reducing Viral Load In Hiv-1 Infected Patients

US Patent:
2010017, Jul 15, 2010
Filed:
Oct 30, 2009
Appl. No.:
12/590005
Inventors:
William C. Olson - Yorktown Heights NY, US
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Downingtown PA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
International Classification:
A61K 39/395
C07K 16/18
US Classification:
4241331, 4241441, 4241781, 5303881, 5303911
Abstract:
This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 logto 2.5 logat about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 logat about nine days following administration of the CCR5 receptor antagonist.

Methods For Reducing Viral Load In Hiv-1 Infected Patients

US Patent:
2011020, Aug 18, 2011
Filed:
Nov 24, 2010
Appl. No.:
12/954464
Inventors:
WILLIAM C. OLSON - OSSINING NY, US
PAUL J. MADDON - SCARSDALE NY, US
DANIEL C. PEVEAR - MEDFORD MA, US
ROBERT J. ISRAEL - SUFFERN NY, US
JOSE D. MURGA - ROSEDALE NY, US
International Classification:
A61K 39/395
A61P 31/18
US Classification:
4241331, 4241431
Abstract:
This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

Methods For Reducing Viral Load In Hiv-1 Infected Patients

US Patent:
2013021, Aug 22, 2013
Filed:
Sep 17, 2012
Appl. No.:
13/621590
Inventors:
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Medford MA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
Assignee:
Progenics Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
US Classification:
4241331, 5303873, 5303896, 4241731
Abstract:
This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 logto 2.5 logat about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 logat about nine days following administration of the CCR5 receptor antagonist.

Methods For Reducing Viral Load In Hiv-1 Infected Patients

US Patent:
2020030, Oct 1, 2020
Filed:
Nov 1, 2019
Appl. No.:
16/672109
Inventors:
- Vancouver WA, US
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Medford MA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
International Classification:
A61K 39/395
C07K 16/28
Abstract:
This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 logto 2.5 logat about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 logat about nine days following administration of the CCR5 receptor antagonist. The viral load reducing dose results in a suppression of mean viral load by 1.0 logwithin about four days following administration of the CCR5 receptor antagonist, and suppression of viral load in the subject persists at or below a level of reduction of 1.0 logfor about two to three weeks. This invention also provides a method of elevating CD4+ cell count in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval an effective HIV-1 viral load-reducing dose of a humanized antibody designated PRO 140, or an anti-CCR5 receptor monoclonal antibody.

Methods For Inhibiting Hiv-1 Replication Involving The Administration Of An Anti-Ccr5 Receptor Monoclonal Antibody And Small Molecule Ccr5 Receptor Antagonist

US Patent:
2014037, Dec 25, 2014
Filed:
Jun 30, 2014
Appl. No.:
14/319505
Inventors:
- Vancouver WA, US
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Medford MA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
International Classification:
A61K 39/39
A61K 31/506
A61K 31/351
A61K 31/46
A61K 31/7072
A61K 31/4178
A61K 38/19
A61K 38/17
A61K 31/551
A61K 39/395
A61K 31/496
US Classification:
4241331, 4241441
Abstract:
This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5CD4 cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

Possible Relatives

Francisco A Murga  Gloria J Murga  Jon Murga  Jorge J Murga  Manuel N Murga  Mario Murga  Miguel A Murga  Jose J Johnson  Jose C White  Jose Joseph 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.